Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Dementia With Lewy Bodies Clinical Trial

Official title:

Imaging Inflammation in Patients With Diffuse Lewy Body Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02702102
• Other study ID #: AAAQ0756
• Secondary ID: 2P50AG008702-26
• Status: Completed
• Phase: Phase 2
• Start date: December 2015
• Est. completion date: September 4, 2019

Study information

• Verified date: October 2019
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body.

11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies.

11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.

Description:

This study is being done to see if 11C-PBR28 could be useful in diffuse Lewy body disease. Diffuse Lewy Body Disease refers to subjects with either Parkinson's disease dementia or dementia with Lewy bodies.

The hypothesis is that 11C-PBR28 binding will be greater in patients with diffuse Lewy body disease than in controls, with largest differences in temporal and limbic regions of the brain.

Participants will have a medical history and examination. This will include questions about thinking and memory. Participants will have blood drawn for routine lab tests. Blood will also be tested for a special genetic test to make sure the 11C-PBR28 scan will work. A special genetic blood test will also be done to see if participants have genes that are associated with dementia with Lewy bodies or other causes of dementia. Participants will not receive the results of these special genetic tests. Participants will also have a magnetic resonance imaging (MRI) scan of the brain.

If a participant still meet the inclusion and exclusion criteria after these procedures are done, then the participant will have one PET scan using 11C-PBR28. This scan will take place at the Columbia University Medical Center Kreitchman PET Center. On the day of the PET scan you will have an intravenous (IV) catheter (tube) placed in the participant's arm. The participant will also have an arterial catheter placed in an artery of your wrist. Participant will be asked to lay down on a PET scanner. A CT scan will be taken of the participant's head. A small amount of 11C-PBR28 will be injected into the IV. A member of the study team will draw blood from the arterial catheter. The PET scan will last 90 minutes. The participant will be asked to lay still during the scan.

The amount of radiation from the 11C-PBR28 PET scan is up to 20 millicuries. Similar amounts of 11C-PBR28 have been given to over 100 human subjects in prior studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: September 4, 2019
• Est. primary completion date: September 4, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Inclusion criteria for patients:

1. Age 60 and older.

2. Meet criteria for either a) dementia with Lewy bodies, or b) Parkinson's disease dementia.

3. Written and oral fluency in English.

4. Able to participate in all scheduled evaluations and to complete all required tests and procedures.

5. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

• Inclusion criteria for controls:

1. Age 60 and older.

2. Normal cognitive and motor function based on neurological examination.

3. Written and oral fluency in English.

4. Able to participate in all scheduled evaluations and to complete all required tests and procedures.

5. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

Exclusion Criteria:

1. Past or present history of certain other brain disorders.

2. Certain significant medical conditions. Examples are uncontrolled epilepsy or multiple serious injuries.

3. Contraindication to MRI scanning.

4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).

5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.

6. Low affinity binding on TSPO genetic screen

7. Currently taking anticoagulant drugs (e.g., warfarin).

8. Women of childbearing potential.

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia
• Dementia With Lewy Bodies
• Diffuse Lewy Body Disease
• Inflammation
• Lewy Body Disease
• Parkinson Disease
• Parkinson's Disease Dementia

Intervention

Drug:
• 11C-PBR28
Up to 20 millicuries

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
William Charles Kreisl	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma)		1 year
Secondary	Relative 11C-PBR28 binding		1 year